Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.186
-0.040 (-17.65%)
At close: Dec 20, 2024, 4:00 PM
0.190
+0.004 (2.10%)
After-hours: Dec 20, 2024, 7:59 PM EST
Aditxt Employees
Aditxt had 47 employees as of December 31, 2023. The number of employees decreased by 14 or -22.95% compared to the previous year.
Employees
47
Change (1Y)
-14
Growth (1Y)
-22.95%
Revenue / Employee
$4,513
Profits / Employee
-$989,379
Market Cap
2.65M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Check-Cap | 85 |
| iCoreConnect | 70 |
| ReShape Lifesciences | 29 |
| Theriva Biologics | 22 |
| Petros Pharmaceuticals | 21 |
| Enveric Biosciences | 7 |
| Quoin Pharmaceuticals | 4 |
| 60 Degrees Pharmaceuticals | 3 |
ADTX News
- 9 days ago - Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Business Wire
- 5 weeks ago - Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - PRNewsWire
- 6 weeks ago - Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares - Business Wire
- 6 weeks ago - Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders - Business Wire
- 6 weeks ago - Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Business Wire
- 6 weeks ago - Evofem Secures Investor Support for Proposed Merger through Voting Agreements - PRNewsWire
- 7 weeks ago - Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - Business Wire
- 7 weeks ago - Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time - Business Wire